lecture title

1、《Targeting cellular and molecular mechanisms of hormonal therapy resistance in prostate cancer》

2. "medical education and pathologist training"

on july 5, 2024, professor huang jiaoti, chairman of the department of pathology at duke university and a world-renowned pathologist, visited jinfeng laboratory and brought a wonderful academic feast to the participants. professor huang jiaoti, with his profound academic foundation and cutting-edge research results, gave an in-depth and simple explanation around the two major themes of "targeted cellular and molecular mechanisms of hormone therapy resistance in prostate cancer" and "medical education and pathologist training" .

leaders attending this lecture include professor bian xiuwu, academician of the chinese academy of sciences and director of the laboratory, tang anming, deputy director of the laboratory, professor cui youhong, assistant director of the laboratory, etc. pathology department leaders and physicians at all levels from many hospitals including the first affiliated hospital of army medical university, chongqing university cancer hospital, and the second affiliated hospital of chongqing medical university were invited to participate, as well as representatives of the scientific research team and technical platform personnel of jinfeng laboratory representatives, a total of 90 people participated in this lecture.

based on his discovery of the pathological morphology of prostate cancer, professor huang jiaoti described his more than 20 years of research and proposed the targeted cellular and molecular mechanisms of hormone therapy resistance in prostate cancer, providing a new strategy for prostate treatment. studies have found that prostate cancer cells express androgen receptors (ar). hormone therapy is one of the main treatments for prostate cancer. its mechanism is to block the production of androgens and inhibit the activity of androgen receptors. however, as the disease progresses, many patients will develop resistance to hormone therapy, resulting in poor treatment efficacy and crpc (castration-resistant prostate cancer). professor huang jiaoti discovered through pathological observation of prostate cancer that there is obvious heterogeneity between and within tumors. there are two different cell types in prostate cancer tissue, including acinar cancer cells and neuroendocrine cells. among them, neuroendocrine cells do not express androgen receptors, making it difficult for traditional anti-androgenic treatments to completely inhibit their proliferation. therefore, neuroendocrine cells may be closely related to recurrence and drug resistance in prostate cancer. further research by professor huang's team found that neuroendocrine cells specifically express cxcr2 receptors, and cxcr2 positivity can inhibit the androgen receptor pathway, causing prostate cancer to become resistant to androgen therapy. furthermore, blocking the il8-cxcr2-p53 pathway is proposed as a new strategy for targeted treatment of prostate cancer. through single-cell sequencing, metabolomics and other methods, professor huang's team also discovered a new surface marker for prostate cancer, glypican-3 (gpc3). studies have shown that gpc3 is highly expressed in prostate cancer tissues and is specifically expressed on human prostate cancer neuroendocrine cells, which has the potential to be used as a surface marker for prostate cancer. at the same time, gpc3 has the potential as a therapeutic target for prostate cancer, including the development of targeted therapeutic drugs or strategies targeting gpc3.

at the same time, professor huang jiaoti gave a comprehensive introduction to the international medical education system and pathologist training process, including curriculum system, physician training, qualification assessment, career development and other aspects. professor huang jiaoti used his own personal experience as an example to describe the experiences of chinese studying, researching and working abroad.

during the exchange session, participating experts had in-depth discussions from multiple perspectives such as career choice, research direction, and future development. the scientific researchers present actively asked questions, and professor huang jiaoti launched a lively academic discussion with everyone.

professor huang jiaoti's report was rich in content and unique insights. it not only broadened the academic horizons of the participants, but also brought to everyone the latest progress and cutting-edge developments in the field of prostate cancer research, focusing on the research hotspot of prostate cancer - resistance to hormone therapy. sex, in-depth elaboration of its complex mechanisms at the cellular and molecular levels, revealing potential therapeutic targets and strategies, opening up a new direction for the clinical treatment of prostate cancer, and providing new insights into the diagnosis, prediction and treatment of prostate cancer and other diseases. ideas and strategies.

introduction to the keynote speakers

professor huang jiaoti is the chairman of the department of pathology at duke university, a tenured professor, and a researcher at the cancer institute. received the honors of duke university distinguished professor and johnston and west chair professor. professor huang jiaoti is a world-renowned pathologist and has profound attainments in the basic and clinical research fields of prostate cancer. professor huang jiaoti has published more than 300 papers in top international magazines such as science, cell, pnas, and new england journal of medicine, chaired and participated in more than 30 us national foundation projects, and served as a review expert for the us nih and department of defense prostate cancer research programs. as well as review experts for national projects in the uk, switzerland, luxembourg and other countries. professor huang jiaoti serves on the editorial board of several international magazines, including modern pathology, a top pathology journal. professor huang jiaoti founded the biotechnology company sisu pharma and served as a consultant to many international pharmaceutical companies, including amgen, seagen inc.